Sight Sciences Inc
NASDAQ:SGHT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.09
8.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Sight Sciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Sight Sciences Inc
NASDAQ:SGHT
|
433.4m USD |
-61%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
217.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
204.1B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
142.6B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.3B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
126.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.7B EUR |
9%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
56.3B USD |
25%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
55.6B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.5B USD |
23%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38B USD |
11%
|
Sight Sciences Inc
Glance View
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sight Sciences Inc's most recent financial statements, the company has Net Margin of -60.6%.